– Enhanced anti-tumor activity of checkpoint antibodies in aggressive CPI-resistant tumors by combining SL-9258 (TIGIT-Fc-LIGHT) with anti-PD(L) 1 –
– bEutrophilin heterodimeric fusion protein of ShttK The GADLEN platform enhanced tumor cell killing by targeting CD19 and CD20 and demonstrated preclinical proof of concept in cancer treatment –
AUSTIN, TX and DURHAM, NC, April 08, 2022 (Globe Newswire) — Shattuck Labs, Inc. (Shattack) (NASDAQ:STTK), is a clinical-stage biotechnology company leading the development of bi-functional fusion proteins as a new class. The Department of Biologic Medicine to treat patients with cancer and autoimmune disease announced preclinical data today at the 2022 American Association for Cancer Research (AACR) annual meeting. This includes data for SL-9258 (TIGIT-Fc-LIGHT) obtained from the company’s ARC. platform, and the company’s Gadlin platform.
“We continue to make excellent progress in our preclinical pipeline,” said Taylor Schreiber, PhD, Shattuck’s chief executive officer. “Data from our SL-9258 compound indicates potent modulation of myeloid cells, T cells, and cytokines, including IL-2, which collectively have better anti-tumor activity than TIGIT and PD-L1 antibodies in preclinical models of PD.” In addition, several compounds in our Gamma Delta T Cell Engager, or GADLEN, platform have shown specific anti-tumor activity in preclinical studies, which is our prime candidate selection and clinical development strategy. We look forward to nominating our next clinical product candidate in 2022.”
The details of the presentations are as follows:
Abstract Title: LIGHT (TNFSF14) with TIGIT blockade expands the activity of costimulation checkpoint inhibitor (CPI) through targeted myeloid cell and effector lymphocyte activation in checkpoint inhibitor refractory and resistant tumors.
Shattuck presented preclinical data for SL-9258 (TIGIT-Fc-LIGHT), a specific fusion protein from its ARC platform, showing that SL-9258 simultaneously confers checkpoint blockade to all tumor-expressed PVR ligands. and enhances the immune cost by known TNF ligands. minor. Light’s ability to bind to and activate CD8+ T and natural killer cells through interaction with one of its receptors known as HVEM and myeloid cells through interaction with its other receptor called LTBR, the checkpoint Primary and acquired resistance translates into strong anti-tumor responses in murine tumors. Model, where TIGIT blocking antibodies exhibit no activity.
TIGIT-Fc-LIGHT was evaluated in non-human primates at doses up to 40 mg/kg and was well tolerated and similar on-target pharmacodynamic activity was observed preclinically characterized in rats Was. Together, these results suggest that TIGIT-Fc-LIGHT may confer clinical benefit to patients who are refractory to conventional checkpoint blockade therapy.
Abstract Title: Specific gamma/delta T cell attachments containing butyrophilin 2A1/3A1 heterodimeric fusion proteins efficiently activate Vg9Vd2+ T cells and promote tumor cell killing
Shattuck presented preclinical data that highlighted the ability of GADLENs to direct gamma delta T cells to kill tumor cells and, in the process, further elucidate tumor cell markers that are important for gamma delta T cell-based therapies. important for its therapeutic activity.
Specific GADLENs of ShttK include heterodimeric BTN2A1 and BTN3A1 extracellular domains linked to the scFv domain via inactive Fc linkers, targeting CD19 or CD20 tumor-antigens, proliferating, degradation and cytokine production in Vg9Vd2+ T cells. Demonstrated ability to inspire. or T cell costimulatory receptor. Furthermore, CD19 and CD20 directed GADLENs enhanced the specific killing of lymphoma cells that expressed both antigen targets.
Additional meeting information can be found on the AACR website, https://www.aacr.org. Posters will be available on the Company’s website under Posters immediately after the event.
Shattuck Labs, Inc. About this
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company that is a leader in the development of bi-functional fusion proteins as a new class of biological medicine to treat patients with cancer and autoimmune disease. Shattuck’s proprietary agonist redirect checkpoint, ARC. compound derived from, the platform simultaneously inhibits checkpoint molecules and activates costimulatory molecules within a single therapeutic. The company’s SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint as well as disturb the CD40 pathway, is being evaluated in two phase 1 trials. A second product candidate, SL-279252 (PD1-Fc-OX40L), is being evaluated in a phase 1 trial in solid tumors or lymphomas. Additionally, the company is rolling out a proprietary gamma delta T cell engager, the Gadlane™, platform, which is designed to attach gamma delta T cells to tumor antigens to treat cancer patients. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information please visit: www.ShattuckLabs.com.
Senior Director, Finance and Investor Relations
Shattuck Labs, Inc.
Stern Investor Relations, Inc.